Mediar Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
238 Main St, Cambridge, Massachusetts, 0...Phone Number
(617) 954-9356Website
www.mediartx.comRevenue
$12.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Mediar Therapeutics
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar's goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach.Explore more
Mediar Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mediar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Mediar Therapeutics is spiking on competitors!
Check if Mediar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Mediar Therapeutics
Funding: Get notified immidiatlly once Mediar Therapeutics has new funding data
Mediar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Mediar Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Mediar Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Mediar Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Mediar Therapeutics
Compare insights from companies similar to Mediar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mediar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mediar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mediar Therapeutics.
Mediar Therapeutics financials insights
Gather financial insights about Mediar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$20M
Series A
$85M
2026
Series B
$76M
Mediar Therapeutics Tech Stack
A closer look at the technologies used by Mediar Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mediar Therapeutics
Sign Up For FreeTo access detailed company insights
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progres... Read More
